| Nome |
# |
|
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial, file dfe4d229-c634-bb0a-e053-d805fe0a78d9
|
29
|
|
Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study, file 07905495-c9c7-49c7-865c-16f1b03b92e7
|
23
|
|
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population, file 9fdd7546-f3fd-4a20-835b-9f69a548cbaa
|
18
|
|
Mechanistic Translation of Melanoma Genetic Landscape in Enriched Pathways and Oncogenic Protein-Protein Interactions, file dfe4d22e-bf74-bb0a-e053-d805fe0a78d9
|
15
|
|
Three-week versus four-week schedule of cisplatin and gemcitabine: Results of a randomized phase II study, file dfe4d229-cb9b-bb0a-e053-d805fe0a78d9
|
14
|
|
Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC, file dfe4d229-cf3c-bb0a-e053-d805fe0a78d9
|
14
|
|
Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: A retrospective analysis, file dfe4d22e-4d9d-bb0a-e053-d805fe0a78d9
|
11
|
|
Efficacy of A Fluoropyrimidine plus Mitomycin C in Pretreated Patients with Metastatic Colorectal Cancer Eligible for Regorafenib: A Retrospective Study, file dfe4d22e-59eb-bb0a-e053-d805fe0a78d9
|
11
|
|
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: Final results of the phase III randomized Short-HER study, file dfe4d22e-6837-bb0a-e053-d805fe0a78d9
|
10
|
|
Early Gastrointestinal Progression to Immunotherapy in Lung Cancer: A Report of Two Cases, file dfe4d22e-b492-bb0a-e053-d805fe0a78d9
|
10
|
|
The "old drug" dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas, file 2a6fc82f-9db3-44a9-8972-cf828b882d59
|
9
|
|
Direct Left Ventricular Metastasis Reduction: 3D-Echo Monitoring For Management of Clinical Case, file dfe4d227-25f3-bb0a-e053-d805fe0a78d9
|
9
|
|
Non-small-cell lung cancer patients unsuitable for first-line chemotherapy: A new category of patients for clinical studies?, file dfe4d229-c3a5-bb0a-e053-d805fe0a78d9
|
9
|
|
Phase ii prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy, file dfe4d229-c7b2-bb0a-e053-d805fe0a78d9
|
9
|
|
Delayed use of eribulin in a heavily pretreated liposarcoma patient, previously misdiagnosed as leiomyosarcoma, file dfe4d22e-3615-bb0a-e053-d805fe0a78d9
|
9
|
|
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida), file dfe4d22e-4d99-bb0a-e053-d805fe0a78d9
|
9
|
|
High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases, file dfe4d22e-61db-bb0a-e053-d805fe0a78d9
|
9
|
|
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial, file dfe4d22e-8331-bb0a-e053-d805fe0a78d9
|
9
|
|
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients, file dfe4d229-cb8d-bb0a-e053-d805fe0a78d9
|
8
|
|
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial, file dfe4d229-cb9d-bb0a-e053-d805fe0a78d9
|
8
|
|
Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer, file dfe4d229-d05e-bb0a-e053-d805fe0a78d9
|
8
|
|
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer, file dfe4d229-d0e0-bb0a-e053-d805fe0a78d9
|
8
|
|
Valutazione economica in base allo studio NAVoTRIAL01 con riferimento al contesto sanitario italiano: Vinorelbine orale e Cisplatino o Pemetrexed e Cisplatino seguiti da mantenimento rispettivamente con Vinorelbine orale e Pemetrexed nel trattamento del Carcinoma Polmonare Non a Piccole Cellule Non Squamoso (NS-NSCLC) in stadio avanzato, file 46b158cd-3f52-4715-82a6-07cfcd1d922f
|
7
|
|
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer, file 924f896a-a0ea-4851-b375-3f90ead13e62
|
7
|
|
Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer, file b506485e-7fcf-40ff-8405-566d21dfba1d
|
7
|
|
Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: A retrospective Italian study, file dfe4d229-c3ab-bb0a-e053-d805fe0a78d9
|
7
|
|
Activity of a specific inhibitor, gefitinib (Iressa™, ZD1839), of epidermal growth factor receptor in refractory non-smal-cell lung cancer, file dfe4d229-c7b7-bb0a-e053-d805fe0a78d9
|
7
|
|
Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer, file dfe4d229-cb95-bb0a-e053-d805fe0a78d9
|
7
|
|
Palbociclib in hormone-receptor-positive advanced breast cancer, file dfe4d229-cf3e-bb0a-e053-d805fe0a78d9
|
7
|
|
Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles, file dfe4d22b-3a6e-bb0a-e053-d805fe0a78d9
|
7
|
|
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer, file dfe4d22e-4d97-bb0a-e053-d805fe0a78d9
|
7
|
|
The impact of the SARS-CoV-2 outbreak on the psychological flexibility and behaviour of cancelling medical appointments of italian patients with pre-existing medical condition: The “impact-COVID-19 for patients” multi-centre observational study, file dfe4d22e-95f2-bb0a-e053-d805fe0a78d9
|
7
|
|
First-line lorlatinib or crizotinib in advanced alk-positive lung cancer, file dfe4d22e-b723-bb0a-e053-d805fe0a78d9
|
7
|
|
Histology-based combination induction chemotherapy for elderly patients with clinical stage III non-small cell lung cancer, file 2fb43f36-cd56-458b-bc18-05e58d8366a9
|
6
|
|
Extensive experience of disease control with gefitinib and the role of prognostic markers, file dfe4d229-c7b9-bb0a-e053-d805fe0a78d9
|
6
|
|
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma, file dfe4d229-cb93-bb0a-e053-d805fe0a78d9
|
6
|
|
Women with synchronous or metachronous lung and ovarian cancer: A multi-institutional report, file dfe4d22e-4da1-bb0a-e053-d805fe0a78d9
|
6
|
|
Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial, file dfe4d22e-59ed-bb0a-e053-d805fe0a78d9
|
6
|
|
Mutational profile of malignant pleural mesothelioma (MPM) in the phase II RAMES study, file dfe4d22e-61de-bb0a-e053-d805fe0a78d9
|
6
|
|
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study), file dfe4d22e-79e8-bb0a-e053-d805fe0a78d9
|
6
|
|
Virtual Multidisciplinary Tumor Boards: A Narrative Review Focused on Lung Cancer, file dfe4d22e-8e02-bb0a-e053-d805fe0a78d9
|
6
|
|
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer, file dfe4d22e-b24c-bb0a-e053-d805fe0a78d9
|
6
|
|
Excision Repair Cross Complementation Group 1 Single Nucleotide Polymorphisms and Nivolumab in Advanced Non-Small Cell Lung Cancer, file dfe4d22e-b725-bb0a-e053-d805fe0a78d9
|
6
|
|
Italian cohort of the nivolumab EAP in squamous NSCLC: Efficacy and safety in patients with CNS metastases, file 20fff379-2e12-4d94-a151-67d0b8d851e5
|
5
|
|
ROC Analysis Identifies Baseline and Dynamic NLR and dNLR Cut-Offs to Predict ICI Outcome in 402 Advanced NSCLC Patients, file d6c093f7-1056-40ea-8ad3-bc931e91c180
|
5
|
|
Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients, file dfe4d229-c7af-bb0a-e053-d805fe0a78d9
|
5
|
|
Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC), file dfe4d229-c7bb-bb0a-e053-d805fe0a78d9
|
5
|
|
Epicure: A European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy, file dfe4d229-cb90-bb0a-e053-d805fe0a78d9
|
5
|
|
Lessons from the ‘iressa’ expanded access programme: Gefitinib in special non-small-cell lung cancer patient populations, file dfe4d229-cb97-bb0a-e053-d805fe0a78d9
|
5
|
|
Prospective study of high-dose chemotherapy and autologous peripheral stem cell transplantation in adult patients with advanced desmoplastic small round-cell tumour, file dfe4d229-cb99-bb0a-e053-d805fe0a78d9
|
5
|
|
Reactions and countermeasures of medical oncologists towards the incoming COVID-19 pandemic: A whatsapp messenger-based report from the Italian college of chief medical oncologists, file dfe4d22e-4d9f-bb0a-e053-d805fe0a78d9
|
5
|
|
Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC, file 1d4b8643-faa9-4dee-aa71-42515b1716e1
|
4
|
|
Cytoreductive surgery and hyperthermic intrapleural chemotherapy for malignant pleural diseases: Preliminary experience, file dfe4d229-cb9f-bb0a-e053-d805fe0a78d9
|
4
|
|
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study, file dfe4d229-cc1b-bb0a-e053-d805fe0a78d9
|
4
|
|
Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study, file dfe4d22e-4d95-bb0a-e053-d805fe0a78d9
|
4
|
|
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407, file dfe4d22e-61e1-bb0a-e053-d805fe0a78d9
|
4
|
|
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib, file dfe4d229-c7b1-bb0a-e053-d805fe0a78d9
|
3
|
|
First-line lorlatinib or crizotinib in advanced alk-positive lung cancer, file dfe4d22e-61dd-bb0a-e053-d805fe0a78d9
|
3
|
|
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer, file dfe4d22e-b24b-bb0a-e053-d805fe0a78d9
|
3
|
|
Pre-operative hyperfractionated radiotherapy and 5-Fluorouracil continuous infusion in elderly patients with locally advanced primary rectal cancer (LA-PRC): feasibility, pathologic complete response, sphincter preservation and local control, file dfe4d227-6a73-bb0a-e053-d805fe0a78d9
|
2
|
|
Phase II trial of alternating intravenous and oral vinorelbine in combination with cisplatin in advanced non-small cell lung cancer, file dfe4d229-c3a4-bb0a-e053-d805fe0a78d9
|
2
|
|
Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma, file dfe4d229-cb8e-bb0a-e053-d805fe0a78d9
|
2
|
|
Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients, file dfe4d22e-b24d-bb0a-e053-d805fe0a78d9
|
2
|
|
Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer, file dfe4d229-c39e-bb0a-e053-d805fe0a78d9
|
1
|
|
Uncommon manifestations of common malignancies - Case 1. Soft-tissue metastases from malignant pleural mesothelioma, file dfe4d229-c7b5-bb0a-e053-d805fe0a78d9
|
1
|
|
Cisplatin plus gemcitabine on days 1 and 4 every 21 days for solid tumors: Result of a dose-intensity study, file dfe4d229-cffe-bb0a-e053-d805fe0a78d9
|
1
|
|
Pleurectomy/decortication and hyperthermic intrapleural chemotherapy for malignant pleural mesothelioma: Initial experience, file dfe4d22a-1e42-bb0a-e053-d805fe0a78d9
|
1
|
|
Benign form of Myasthenia Gravis after Nivolumab treatment, file dfe4d22b-c91e-bb0a-e053-d805fe0a78d9
|
1
|
|
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients, file dfe4d22e-4d9b-bb0a-e053-d805fe0a78d9
|
1
|
|
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial, file dfe4d22e-8e04-bb0a-e053-d805fe0a78d9
|
1
|
| Totale |
480 |